Ankylosing spondylitis and osteoporosis;Spondylarthrite ankylosante et ostéoporose

Revue de Medecine Interne

Volumn 27, Issue 5, 2006, Pages 392-399

  Ardizzone, M ^a   Javier, R M ^a   Kuntz, J L ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Absorptiometry; Ankylosing spondylitis; Bisphosphonates; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CORTICOSTEROID; ETANERCEPT; ETIDRONIC ACID; INFLIXIMAB; METHOTREXATE; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL MARKER;

ANKYLOSING SPONDYLITIS; BIOCHEMISTRY; BIOPSY; BONE DENSITOMETRY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CERVICAL SPINE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HISTOLOGY; HUMAN; INFLAMMATION; INTERVERTEBRAL DISK; LIGAMENT; LUMBAR SPINE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; RHEUMATIC DISEASE; RISK ASSESSMENT; SCREENING; SHORT SURVEY; VERTEBRA FRACTURE; CLASSIFICATION; FEMALE; MALE; PATHOLOGY; REVIEW;

BIOLOGICAL MARKERS; BIOPSY; FEMALE; HUMANS; MALE; OSTEOPOROSIS; SPONDYLITIS, ANKYLOSING;

EID: 33646094712     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.09.008     Document Type: Short Survey

References (57)

1. Saraux A., Guillemin F., Guggenbuhl P., Roux CH., Fardellone P., LeBihan E., et al. Prevalence of spondylarthropathies in France-2001. Ann. Rheum. Dis. 64 (2005) 1431-1435
2. Cooper C., Carbone L., Michet C.J., Atkinson E.J., O'Fallon W.M., and Melton L.J. Fracture risk in patients with ankylosing spondylitis: a population based study. J. Rheumatol. 21 (1994) 1877-1882
3. Hanson C.A., Shargrin J.W., and Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin. Orthop. Relat. Res. 74 (1971) 59-64
4. Ralston S.H., Urquhart G., Brzeski M., and Sturrock R.D. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 300 (1990) 563-565
5. Blanc B., Bregeon C., and Colin D. Les fractures du rachis au cours de la spondylarthrite ankylosante. In: Simon L., et al. (Ed). La spondylarthrite ankylosante, actualités nosologiques et thérapeutiques (1988), Masson, Paris 230-242
6. Hunter T., and Dubo H.J. Spinal fractures complicating ankylosing spondylitis. A long-term followup study. Arthritis Rheum. 26 (1983) 751-759
7. El Maghraoui A., Borderie D., Cherruau B., Edouard R., Dougados M., and Roux C. Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J. Rheumatol. 26 (1999) 2205-2209
8. Reid D.R., Nicoll J.J., Kennedy N.S.J., Smith M.A., Tothill P., and Nuki G. Bone mass in ankylosing spondylitis. J. Rheumatol. 13 (1986) 932-935
9. Will R., Bhalla A.K., Palmer R., Ring F., and Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event?. Lancet 2 (1989) 1483-1485
10. Will R., Palmer R., Bhalla A.K., Ring F., and Calin A. Bone loss as well as bone formation is a feature of progressive ankylosing spondylitis. Br. J. Rheum. 29 (1990) 498-499
11. Bronson W.D., Walker S.E., and Allen S.A. Osteoporosis in ankylosing spondylitis: Hidden loss of vertebral body bone mass detected by dual energy X-Ray absorbtiometry. Arthritis Rheum. 35 (1992) 243
12. Devogelaer J.P., Maldague B., and Malghem J. Appendicular and vertebral bone mass in ankylosing spondylitis. Arthritis Rheum. 35 (1992) 1062-1067
13. Donnelly S., Doyle D.V., Rolfe I., Mc Closkey E.V., and Spector T.D. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann. Rheum. Dis. 53 (1994) 117-121
14. Mullaji A.B., Upadhyay S.S., and Ho E.K.W. Bone mineral density in ankylosing spondylitis. J. Bone Joint Surg. 76 (1994) 660-665
15. Sivri A., Kilinc S., Gokce-Kutsal Y., and Ariyuzek N. Bone mineral density in ankylosing spondylitis. Clin. Rheumatol. 15 (1996) 51-54
16. Bronson W.D., Walker S.E., Hillman L.S., Keisler D., Hoyt T., and Allen S.H. Bone Mineral Density and Biochemical Markers of Bone Metabolism in ankylosing spondylitis. J. Rheumatol. 25 (1998) 929-935
17. Meirelles E.S., Borelli A., and Camargo O.P. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin. Rheumatol. 18 (1999) 364-368
18. Mitra D., Elvins D.M., and Collins A.J. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J. Rheumatol. 26 (1999) 2201-2204
19. Juanola X., Mateo L., Nolla J.M., Roig-Vilaseca D., Campoy E., and Roig-Escofet D. Bone Mineral Density in women with ankylosing spondylitis. J. Rheumatol. 27 (2000) 1028-1031
20. Mitra D., Elvins D.M., Speden D.J., and Collins A.J. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatol. 39 (2000) 85-89
21. Dos Santos F.P., Constantin A., Laroche M., Destombes F., Bernard J., Mazières B., et al. Whole body and regional bone mineral density in ankylosing spondilitis. J. Rheumatol. 28 (2001) 547-549
22. Speden D.J., Calin A.I., Ring F.J., and Bhalla A.K. Bone mineral density, calcaneal ultrasound and bone turnover markers in women with ankylosing spondilitis. J. Rheumatol. 29 (2002) 516-521
23. Capaci K., Hepguler S., Argin M., and Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med. J. 44 (2003) 379-384
24. Malterre L., Schaeverbeke T., Lequen L., Chene G., Bannwarth B., and Dehais J. Densité minérale et métabolisme osseux des spondylarthropathies. Rev. Med. Int. 26 (2005) 381-385
25. Jansen T.L., Aarts M.H., Zanen S., and Bruyn G.A. Risk assessment for osteoporosis by quantitative ultrasound the heel in ankylosing spondylitis. Clin. Exp. Rheumatol. 21 (2003) 599-604
26. Gratacos A., Collado A., Pons F., Osaba M., Sanmarti R., Roque M., et al. Significant loss of bone mass in patients with early active ankylosing spondylitis. Arthritis Rheum. 42 (1999) 2319-2324
27. Toussirot E., Michel F., and Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 40 (2001) 882-888
28. Gilgil E., Kacar C., Tuncer T., and Butun B. The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J. Rheumatol. 32 (2005) 292-294
29. Szejnfeld V.L., Monier-Faugere M.C., Bognar B.J., Ferraz M.B., and Malluche H.H. Systemic osteopenia and mineralization defect in ankylosing spondylitis. J. Rheumatol. 24 (1997) 683-688
30. Lee Y.S.L., Scholzhauer T., Ott S.M., Van Vollenhoven R.F., Hunter J., Shapiro J., et al. skeletal status of men with early and late ankylosing spondylitis. Am. J. Med. 103 (1997) 233-241
31. Franck H., and Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann. Rheum. Dis. 52 (1993) 343-346
32. Lange U., Teichmann J., and Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur. J. Med. Res. 29 (2000) 507-511
33. Toussirot E., Ricard-Blum S., Dumoulin G., Cedoz J.P., and Wendling D. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 38 (1999) 21-27
34. Toussirot E., Nguyen N.U., Dumoulin G., Regnard J., and Wendling D. Insulin-like growth factor I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis. Br. J. Rheum. 37 (1998) 1172-1176
35. Gratacos J., Collado A., Filella X., Sanmarti R., Canete J., Llena J., et al. Serum cytokines (IL-6, TNF-alpha, IL1-beta, IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL6 and disease activity and severity. Br. J. Rheum. 33 (1994) 927-931
36. Armour K.E., Van't Hof R.J., Grabowski P.S., Reid D.M., and Ralston S.H. Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J. Bone Miner. Res. 14 (1999) 2137-2142
37. Lange U., Jung O., Teichmann J., and Neeck G. Relationhips between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos. Int. 12 (2001) 1031-1035
38. Lane N.E., and Goldring S.R. Bone loss in Rheumatoid arthritis: what role does inflammation play?. J. Rheumatol. 25 (1998) 1282-1289
39. Franck H., Meurer T., and Hofbauer L.C. Evaluation of bone mineral density, hormones, biochemical marker bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondilitis. J. Rheumatol. 31 (2004) 2236-2241
40. Verhoeven A.C., and Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J. Rheumatol. 24 (1997) 1495-1503
41. Buckley L.M., Leib E.S., Cartularo K.S., Vacek P.M., and Cooper S.M. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J. Rheumatol. 24 (1997) 1489-1494
42. Di Munno O., Mazzantini M., Sinigaglia L., Bianchi G., Minisola G., Muratore M., et al. effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectionnal study. J. Rheumatol. 31 (2004) 1305-1309
43. Davis Jr. J.C., Huang F., and Maksymowych W.P. New therapies for ankylosing spondylitis: etanercept, thalidomide, pamidronate. Rheum. Dis. Clin. North Am. 29 (2003) 481-494
44. Reid I.R. Bisphosphonates: new indications and methods of administration. Curr. Opin. Rheumatol. 15 (2003) 458-463
45. Maksymowych W.P., Jhangri G.S., Leclercq S., Skeith K., Yan A., and Russell A.S. An open study of pamidronate in the treatement of refractory ankylosing spondylitis. J. Rheumatol. 25 (1998) 714-717
46. Maksymowych W.P., Lambert R., Jhangri G.S., Leclercq S., Chiu Ben Wong P., Aaron S., et al. Clinical and radiological amelioration of refractory peripheral spondylarthritis by pulse intravenous pamidronate therapy. J. Rheumatol. 28 (2001) 144-155
47. Maskymowych W.P., Jhangui G.S., Fitzgerald A., Leclercq S., Chiu P., Yan A., et al. A six-month randomized (60 vs 10mg) in the treatment of nonsteroid antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 46 (2002) 766-773
48. Santini D., Fratto M.E., Vincenzi B., La Cesa A., Dianzani C., and Tonini G. Bisphosphonate effect in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokines activities. BioDrugs 18 (2004) 269-278
49. Mitra D., O'Neill T., Elvins D., Collins A., and Bhalla A. The efficacy of etidronate on disease activity, markers of bone turnover and BMD in early AS and osteoporosis. Arthritis Rheum. 38 (1995) S349 (abstract)
50. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observationnal, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 48 (2003) 2224-2233
51. Temekonidis T.I., Alamanos Y., Nikas S.N., Bougias D.V., Georgiadis A.N., Voulgari D., et al. Infliximab therapy in patients with ankylosing spondylitis: an open label month study. Ann. Rheum. Dis. 62 (2003) 1218-1220
52. Wendling D., Claudepierre P., Lohse A., Toussirot E., and Breban M. Utilisation thérapeutique des agents anti-TNF alpha au cours des spondylarthropathies. Presse Med. 32 (2003) 1517-1524
53. Allali F., Breban M., Porcher R., Maillefert J.F., Dougados M., and Roux C. Increase in bone mineral density of patients with spondylarthropathy treated with anti tumour necrosis factor alpha. Ann. Rheum. Dis. 62 (2003) 347-349
54. Davis Jr. J., Webb A., Lund S., and Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum. 51 (2004) 302-304
55. Demis E., Roux C., Breban M., and Dougados M. Infliximab in spondylarthropathy, influence on bone density. Clin. Exp. Rheumatol. 20 (2002) 185-186
56. Bessant R., Harris C., and Keat A. Audit of the diagnosis, assessement and treatment of the osteoporosis in patients with ankylosing spondylitis. J. Rheumatol. 30 (2003) 779-782
57. Bessant R., and Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis?. J. Rheumatol. 29 (2002) 1511-1519